Safety, tolerability, pharmacokinetics, and pharmacodynamics of oral JMKX003002 in Chinese healthy participants: a randomized, double-blind, placebo-controlled, single- and multiple-ascending dose, and food-effect phase I clinical trial

Objective To evaluate the safety, tolerability, pharmacokinetics (PK), and pharma­codynamics (PD) of the sodium-hydrogen exchanger 3 (NHE3) inhibitor JMKX003002 in Chinese healthy participants.Patients and methods This phase I, randomized, double-blind, placebo-controlled study included a single-asc...

Whakaahuatanga katoa

Ngā taipitopito rārangi puna kōrero

Ngā kaituhi matua:	Guoying Cao, Xiaomeng Mao, Xiaojie Wu, Nanyang Li, Haijing Yang, Jingjing Wang, Jicheng Yu, Jingqiu Hu, Lingli Zhang, Jingyun Chen, Jing Zhang
Hōputu:	Artigo
Reo:	Inglês
I whakaputaina:	Taylor & Francis Group 2026-12-01
Rangatū:	Annals of Medicine
Ngā marau:	Sodium-hydrogen exchanger 3 inhibitor hyperphosphatemia safety pharmacokinetics pharmacodynamics JMKX003002
Urunga tuihono:	https://www.tandfonline.com/doi/10.1080/07853890.2026.2701494
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!